clinical trial · NCT04794101
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Janssen Research & Development, LLC·phase3·active not recruiting·n = 97
X-Linked Retinitis PigmentosaGenetic: AAV5-hRKp.RPGR Intermediate DoseGenetic: AAV5-hRKp.RPGR Low Dose
brief summary
A clinical trial of AAV5-hRKp.RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
started
Dec 4, 2020
primary completion
Sep 20, 2029
completion
Dec 7, 2029
last updated
Jun 5, 2026
official title
Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol